Latest Healthcare News

Arena REIT delivered a robust HY2025 performance with statutory net profit soaring 87%, underpinned by strategic acquisitions and development completions. The REIT reaffirmed its FY2025 distribution guidance, signaling confidence in sustained growth amid a strong social infrastructure portfolio.

Arena REIT reports a striking 87% increase in net profit for the half-year ended December 2024, driven by property revaluations and rental growth. Distributions per security also rose, reflecting confidence in the group’s long-term strategy.

Cann Group Limited has negotiated an extension of its NAB loan maturity and deferred upcoming interest payments, providing crucial breathing room for its capital projects and working capital needs.

SomnoMed Limited prepares to unveil its H1FY25 financial results on February 28, 2025, accompanied by a live investor presentation and Q&A session. The company remains a global leader in sleep apnea treatment solutions.

Ramsay Health Care has announced a significant $305 million impairment in its UK segment driven by challenges at Elysium, alongside a $64.5 million tax provision release linked to Ramsay Santé. The company is taking decisive steps to address operational weaknesses while its core UK hospitals show promising growth.

Charter Hall Social Infrastructure REIT delivered a solid 2025 half-year performance, maintaining distribution guidance while enhancing its portfolio through key acquisitions and divestments. The REIT’s outlook brightens with an increased full-year distribution forecast.

Charter Hall Social Infrastructure REIT reported solid half-year results for 1H FY25, underpinned by strong earnings, active portfolio management, and an upgraded distribution guidance. The REIT’s acquisition of a high-yield pathology laboratory and divestment of childcare assets highlight its strategic repositioning.

Alcidion has secured its first contract in Wales with Hywel Dda University Health Board, deploying its Miya Precision Platform to enhance patient flow and clinical communication over five years.

CSL Limited has announced a USD 1.30 per share dividend for the half-year ending December 2024, marking a steady return for investors despite the payout being fully unfranked.

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.

CSL Limited posted a robust half-year performance with NPATA rising 5% at constant currency, driven by strong growth in CSL Behring and CSL Vifor despite challenges in its influenza vaccine segment. The company reaffirmed its FY25 guidance, anticipating double-digit earnings growth.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.